Ono Pharmaceutical Co., Ltd. (OPHLF)
USD 10.89
(0.0%)
USD 10.89
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 212.44 Billion JPY | 8.86% |
| 2023 | 195.16 Billion JPY | 18.53% |
| 2022 | 164.65 Billion JPY | 31.32% |
| 2021 | 125.38 Billion JPY | -7.72% |
| 2020 | 135.86 Billion JPY | -4.85% |
| 2019 | 142.79 Billion JPY | 5.18% |
| 2018 | 135.76 Billion JPY | 26.89% |
| 2017 | 106.98 Billion JPY | 21.23% |
| 2016 | 88.25 Billion JPY | 2.8% |
| 2015 | 85.84 Billion JPY | 2.1% |
| 2014 | 84.07 Billion JPY | 5.77% |
| 2013 | 79.48 Billion JPY | 0.76% |
| 2012 | 78.88 Billion JPY | 4.77% |
| 2011 | 75.29 Billion JPY | -0.02% |
| 2010 | 75.3 Billion JPY | 4.93% |
| 2009 | 71.76 Billion JPY | -1.35% |
| 2008 | 72.74 Billion JPY | 7.32% |
| 2007 | 67.78 Billion JPY | -3.05% |
| 2006 | 69.91 Billion JPY | 8.84% |
| 2005 | 64.24 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 62.65 Billion JPY | 18.44% |
| 2024 Q1 | 48.49 Billion JPY | -22.43% |
| 2024 Q3 | 52.9 Billion JPY | 9.27% |
| 2024 FY | 209.1 Billion JPY | 7.14% |
| 2024 Q2 | 48.41 Billion JPY | -0.17% |
| 2023 Q4 | 62.51 Billion JPY | 25.22% |
| 2023 Q2 | 41.09 Billion JPY | -1.27% |
| 2023 Q1 | 41.62 Billion JPY | -9.56% |
| 2023 FY | 195.16 Billion JPY | 18.53% |
| 2023 Q3 | 49.92 Billion JPY | 21.48% |
| 2022 Q3 | 48.29 Billion JPY | 35.77% |
| 2022 Q4 | 46.02 Billion JPY | -4.69% |
| 2022 FY | 164.65 Billion JPY | 31.32% |
| 2022 Q1 | 34.77 Billion JPY | -10.35% |
| 2022 Q2 | 35.56 Billion JPY | 2.29% |
| 2021 Q2 | 29 Billion JPY | 6.22% |
| 2021 Q1 | 27.3 Billion JPY | -28.45% |
| 2021 FY | 125.38 Billion JPY | -7.72% |
| 2021 Q4 | 38.78 Billion JPY | 28.09% |
| 2021 Q3 | 30.28 Billion JPY | 4.39% |
| 2020 Q3 | 32.23 Billion JPY | 0.14% |
| 2020 FY | 135.86 Billion JPY | -4.85% |
| 2020 Q4 | 38.16 Billion JPY | 18.39% |
| 2020 Q2 | 32.19 Billion JPY | -3.25% |
| 2020 Q1 | 33.27 Billion JPY | -13.21% |
| 2019 Q2 | 34.5 Billion JPY | 4.18% |
| 2019 Q3 | 36.84 Billion JPY | 6.79% |
| 2019 FY | 142.79 Billion JPY | 5.18% |
| 2019 Q4 | 38.33 Billion JPY | 4.05% |
| 2019 Q1 | 33.11 Billion JPY | -11.96% |
| 2018 Q4 | 37.61 Billion JPY | 10.71% |
| 2018 Q3 | 33.97 Billion JPY | 4.01% |
| 2018 Q2 | 32.66 Billion JPY | 3.72% |
| 2018 Q1 | 31.49 Billion JPY | 45.05% |
| 2018 FY | 135.76 Billion JPY | 26.89% |
| 2017 Q4 | 21.71 Billion JPY | -27.4% |
| 2017 FY | 106.98 Billion JPY | 21.23% |
| 2017 Q2 | 30.05 Billion JPY | 18.73% |
| 2017 Q1 | 25.31 Billion JPY | -10.05% |
| 2017 Q3 | 29.91 Billion JPY | -0.47% |
| 2016 Q4 | 28.13 Billion JPY | 23.58% |
| 2016 Q1 | 14.79 Billion JPY | -32.15% |
| 2016 Q2 | 22.55 Billion JPY | 52.42% |
| 2016 FY | 88.25 Billion JPY | 2.8% |
| 2016 Q3 | 22.76 Billion JPY | 0.97% |
| 2015 Q2 | 21.93 Billion JPY | 5.8% |
| 2015 FY | 85.84 Billion JPY | 2.1% |
| 2015 Q4 | 21.8 Billion JPY | 2.0% |
| 2015 Q3 | 21.37 Billion JPY | -2.52% |
| 2015 Q1 | 20.72 Billion JPY | -1.45% |
| 2014 FY | 84.07 Billion JPY | 5.77% |
| 2014 Q2 | 20.77 Billion JPY | -2.71% |
| 2014 Q3 | 20.91 Billion JPY | 0.65% |
| 2014 Q4 | 21.03 Billion JPY | 0.58% |
| 2014 Q1 | 21.35 Billion JPY | -1.76% |
| 2013 Q3 | 36.91 Billion JPY | 226.87% |
| 2013 FY | 79.48 Billion JPY | 0.76% |
| 2013 Q1 | 9.54 Billion JPY | -79.74% |
| 2013 Q4 | 21.73 Billion JPY | -41.11% |
| 2013 Q2 | 11.29 Billion JPY | 18.33% |
| 2012 Q4 | 47.11 Billion JPY | 387.91% |
| 2012 Q3 | 9.65 Billion JPY | -24.2% |
| 2012 Q2 | 12.73 Billion JPY | 35.81% |
| 2012 Q1 | 9.38 Billion JPY | -78.39% |
| 2012 FY | 78.88 Billion JPY | 4.77% |
| 2011 Q1 | 8.02 Billion JPY | -82.82% |
| 2011 Q2 | 15.48 Billion JPY | 92.98% |
| 2011 Q4 | 43.41 Billion JPY | 418.56% |
| 2011 FY | 75.29 Billion JPY | -0.02% |
| 2011 Q3 | 8.37 Billion JPY | -45.93% |
| 2010 Q1 | 6.94 Billion JPY | -63.01% |
| 2010 FY | 75.3 Billion JPY | 4.93% |
| 2010 Q2 | 11.76 Billion JPY | 69.39% |
| 2010 Q3 | 9.88 Billion JPY | -16.03% |
| 2010 Q4 | 46.7 Billion JPY | 372.6% |
| 2009 FY | 71.76 Billion JPY | -1.35% |
| 2009 Q2 | 9.5 Billion JPY | 0.0% |
| 2009 Q4 | 18.78 Billion JPY | 4.45% |
| 2009 Q3 | 17.98 Billion JPY | 89.27% |
| 2008 FY | 72.74 Billion JPY | 7.32% |
| 2007 FY | 67.78 Billion JPY | -3.05% |
| 2006 FY | 69.91 Billion JPY | 8.84% |
| 2005 FY | 64.24 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AstraZeneca PLC | 29.57 Billion USD | -618.247% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.07 Billion USD | -1144.467% |
| CSPC Pharmaceutical Group Limited | 2.14 Billion USD | -9795.053% |
| Clarus Therapeutics Holdings, Inc. | 50.96 Million USD | -416708.256% |
| Novartis AG | 24.87 Billion USD | -754.18% |
| PT Kalbe Farma Tbk. | 11823.24 Billion USD | 98.203% |